PuSH - Publikationsserver des Helmholtz Zentrums München

Malnati, M.S.* ; Heltai, S.* ; Cosma, A. ; Reitmeir, P. ; Allgayer, S. ; Glashoff, R.H.* ; Liebrich, W.* ; Vardas, E.* ; Imami, N.* ; Westrop, S.* ; Nozza, S.* ; Tambussi, G.* ; Buttò, S.* ; Fanales-Belasio, E.* ; Ensoli, B.* ; Ensoli, F.* ; Tripiciano, A.* ; Fortis, C.* ; Lusso, P.* ; Poli, G.* ; Erfle, V. ; Holmes, H.*

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

J. Immunol. Methods 375, 46-56 (2012)
Verlagsversion DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Delineation of the immune correlates of protection in natural infection or after vaccination is a mandatory step for vaccine development. Although the most recent techniques allow a sensitive and specific detection of the cellular immune response, a consensus on the best strategy to assess their magnitude and breadth is yet to be reached. Within the AIDS Vaccine Integrated Project (AVIP http://www.avip-eu.org) we developed an antigen scanning strategy combining the empirical-based approach of overlapping peptides with a vast array of database information. This new system, termed Variable Overlapping Peptide Scanning Design (VOPSD), was used for preparing two peptide sets encompassing the candidate HIV-1 vaccine antigens Tat and Nef. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets in a trial involving six laboratories of the AVIP consortium. Cross-reactive background responses were measured in 80 HIV seronegative donors (HIV-), while sensitivity and magnitude of Tat and Nef-specific T-cell responses were assessed on 90 HIV+ individuals. In HIV-, VOPSD peptides generated background responses comparable with those of the standard sets. In HIV-1+ individuals the VOPSD pools showed a higher sensitivity in detecting individual responses (Tat VOPSD vs. Tat 15mers or 20mers: p≤0.01) as well as in generating stronger responses (Nef VOPSD vs. Nef 20mers: p<0.001) than standard sets, enhancing both CD4 and CD8 T-cell responses. Moreover, this peptide design allowed a marked reduction of the peptides number, representing a powerful tool for investigating novel HIV-1 candidate vaccine antigens in cohorts of HIV-seronegative and seropositive individuals.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Peptide; Tat; Nef; ELISpot; HIV-1; Vaccine
ISSN (print) / ISBN 0022-1759
e-ISSN 1872-7905
Quellenangaben Band: 375, Heft: 1-2, Seiten: 46-56 Artikelnummer: , Supplement: ,
Verlag Elsevier
Begutachtungsstatus Peer reviewed